#FunctionalMedicine #NavigatingMS #BiomarkersExplained
Hi there, I'm Dr. Ken Sharlin, here to shed light on a complex part of your journey with multiple sclerosis (MS) - biomarkers. These intriguing little indicators can tell us so much about your condition, including its activity, progression, and severity, as well as how your body responds to therapy.
In this video, I'll be explaining what biomarkers are, and how they help us diagnose MS, distinguishing it from other neurological conditions. I'll also delve into how they can predict the prognosis and risk of relapse or cognitive decline in MS patients.
I'll focus on specific biomarkers like neurofilament light chain and glial fibrillary acidic protein (GFAP). These can provide valuable insights, but they're not without their challenges. We'll explore issues such as inconsistency and lack of standardization, which can make their use tricky.
Lastly, I'll share my personal experience using serum Neurofilament Light (NFL) chain and GFAP in my practice at Sharlin Health and Neurology. My goal is to simplify this crucial information, making it more approachable and understandable for you and your loved ones. Remember, we're in this together, navigating the complex world of MS one step at a time.
Plus, if you have an idea of something you want me to cover, please let me know because I want to serve my community. Post a comment below
Let's connect:
Website: www.functionalmedicine.doctor
Free Discovery Call: functionalmedicine.doctor/fun...
Facebook Page: / sharlinhealthandneurology
Facebook Private Group: / shneurofitness
Instagram: / sharlinhealthandneurology
Contact Email: callie@sharlinfxmed.com
Contact Phone: 417-485-4330
** The information in this video is not intended nor implied to be a substitute for professional medical advice, diagnosis, or treatment. All content, including text, graphics, images, and information, contained in this video is for general informational purposes only and does not replace a consultation with your own doctor/health professional **
5 авг 2024
